Please cite this article in press Nabil Saad Al-saedi et al, An Overview Of Benefits And Side Effects Of Carboxymaltose Injection, Indo Am. J. P. Sci, 2023; 10 (09).

1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009;12(4):444–454.
2. Umbreit J. Iron deficiency: a concise review. Am J Hematol. 2005;78(3):225–231.
3. Shander A, Goodnough LT, Javidroozi M, Auerbach M, Carson J, Ershler WB, et al. Iron deficiency anemia: bridging the knowledge and practice gap. Transfus Med Rev. 2014;28(3):156–166.
4. Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol. 2012;24(2):109–116.
5. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritinconcentration. Blood. 2011;118(12):3222–3227.
6. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Haematol. 2013;88(2):97–101.
7. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101(1):67–73.
8. Bisbe E, García-Erce JA, Díez-Lobo AI, Muñoz M. Anaemia Working Group España. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107(3):477–478.
9. Muñoz M, García-Erce JA, Cuenca J, Bisbe E, Naveira E, AWGE (Spanish Anaemia Working Group) On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery. Blood Transfus. 2012;10(1):8–22.
10. Sachdev H, Gera T, Nestel P. Effect of iron supplementation on mental and motor development in children: systematic review of randomised controlled trials. Public Health Nutr. 2005;8(2):117–132.
11. Glazer Y, Bilenko N. Effect of iron deficiency and iron deficiency anemia in the first two years of life on cognitive and mental development during childhood. Harefuah. 2010;149(5):309–314,335.
12. Gasche C, Lomer MCE, Cavill I, Weiss G. Iron, anemia, and inflammatory bowel diseases. Gut. 2004;53(8):190–197.
13. Rapp S., Feldman S., Exum M., Fleischer A., Jr, Reboussin D. (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41: 401–407.
14. Rimon E., Levy S., Sapir A., Gelzer G., Peled R., Ergas D., et al. (2002) Diagnosis of iron deficiency anemia in the elderly by transferrin receptor-ferritin index. Arch Intern Med 162: 445–449.
15. Ruz M., Carrasco F., Rojas P., Codoceo J., Inostroza J., Rebolledo A., et al. (2009) Iron absorption and iron status are reduced after Roux-en-Y gastric bypass. Am J Clin Nutr 90: 527–532.
16. Santiago P. (2012) Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Scientific World Journal 2012: 846824.
17. Short M., Domagalski J. (2013) Iron deficiency anemia: evaluation and management. Am Fam Physician 87: 98–104.
18. Stein J, Dignass A. (2012) Management of iron deficiency anemia in inflammatory bowel disease–a practical approach. Ann Gastroenterol 26: 104–113.
19. Thomas C., Thomas L. (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48: 1066–1076.
20. Tussing-Humphreys L., Pusatcioglu C., Nemeth E., Braunschweig C. (2012) Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin. J Acad Nutr Diet 112: 391–400.
21. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci. 2010;55(3):548–559.
22. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89:1052–1057.
23. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron deficiency anemia in adults. Am J Med. 2008;121(11):943–948.
24. Maslovsky I. Intravenous iron in a primary-care clinic. Am J Hematol. 2005;78:261–264.
25. Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier P, Laxenaire MDMC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol. 2002;186(3):518–522.
26. al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;69:121–124.
27. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol. 2005;106:1335–1340.
28. Dhanani JV, Ganguly BP, Chauhan LN. Comparison of efficacy and safety of two parenteral iron preparations in pregnant women. J Pharmacol Pharmacother. 2012;3(4):314–319.
29. Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and effi- cacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia 2012;2012:172104.
30. Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R. Ran- domized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleed- ing. Int J Gynaecol Obstet 2016;133:43-8.
31. Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE: Randomized evalua- tion of efficacy and safety of ferric carboxy- maltose in patients with iron deficien- cy anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant 2010; 25: 2368– 2375.
32. Schaefer RM, Khasabov NN, Todorov NG, et al: The efficacy and safety of intravenous fer- ric carboxymaltose compared to iron su- crose in haemodialysis patients with iron de- ficiency anaemia. 45th Congress of the Euro- pean Renal Association and the European Dialysis and Transplant Association, Stock- holm, May 10–13, 2008.
33. Qunibi M: Safety and tolerability profile of ferric carboxymaltose (FCM), a new high dose intravenous iron, across ten multi-cen- ter clinical trials. 40th Annual Meeting of the American Society of Nephrology, San Francisco, November 2–5, 2007.
34. Evstatiev R., Alexeeva O., Bokemeyer B., Chopey I., Felder M., Gudehus M., et al. (2013) Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11: 269–277.
35. Giannoulis C, Daniilidis A, Tantanasis T, Tzafettas J. Intravenous administration of iron sucrose for treating anemia in postpartum women. Hippokratia. 2009;13(1):38–40.
36. 34. Aggarwal RS, Mishra VV, Panchal NA, Patel NH, Deshchougule VV, Jasani AF. Comparison of oral iron and IV iron sucrose for treatment of anemia in postpartum Indian women. Natl J Community Med. 2012;3:48–54.
37. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women–PREFER a randomized, placebo-controlled study. PLoS One. 2014;9(4):e94217.